Home

Press Releases

12345678910
AEye Reports Second Quarter 2025 Results
AEye, Inc. (Nasdaq: LIDR), a pioneer in high-performance lidar technology and creator of the Apollo lidar sensor, today announced its results for the second quarter ended June 30, 2025.
By AEye, Inc. · Via Business Wire · July 31, 2025
LPL Financial Announces Second Quarter 2025 Results
Key Financial Results:
By LPL Financial Holdings, Inc. · Via GlobeNewswire · July 31, 2025
Stryker reports second quarter 2025 operating results
Portage, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2025:
By Stryker Corporation · Via GlobeNewswire · July 31, 2025
iRhythm Technologies Announces Second Quarter 2025 Financial Results
SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025.
By iRhythm · Via GlobeNewswire · July 31, 2025
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
By Resmed, Inc. · Via GlobeNewswire · July 31, 2025
Shenandoah Telecommunications Company Reports Second Quarter 2025 Results
EDINBURG, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announced second quarter 2025 financial and operating results.
Exponent Declares Regular Quarterly Dividend for Q3 2025
MENLO PARK, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share of common stock to be paid on September 19, 2025, to all common stockholders of record as of September 5, 2025.
By Exponent, Inc. · Via GlobeNewswire · July 31, 2025
Rackspace Receives SBTi Approval for Net-Zero Targets, Reinforcing Commitment to Sustainable Operations and Innovation
Framework sets new standard for helping customers meet their sustainability goals and Scope 3 reporting requirements
By Rackspace US, Inc. · Via GlobeNewswire · July 31, 2025
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
Company expects to complete Phase 3 Aspire study in the second half of 2026
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT
By Alector, Inc. · Via GlobeNewswire · July 31, 2025
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States
By LENZ Therapeutics, Inc. · Via GlobeNewswire · July 31, 2025
Zoom to Release Financial Results for the Second Quarter of Fiscal Year 2026
SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, after the market closes.
By Zoom Communications, Inc. · Via GlobeNewswire · July 31, 2025
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
EMERYVILLE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive results from the SPECTRA clinical trial evaluating 4D-150 in patients with diabetic macular edema (DME), and alignment with the European Medicines Agency (EMA) on a registrational pathway for 4D-150 in DME. The data, which included both the 52-week primary endpoint and 60-week analyses, were presented by David Almeida, M.D., MBA, Ph.D., Erie Retina Research in an oral presentation titled “Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Diabetic Macular Edema” at the 43rd Annual American Society of Retina Specialists (ASRS) Scientific Meeting.
Exponent Reports Second Quarter 2025 Financial Results
MENLO PARK, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the second quarter of fiscal year 2025 ended July 4, 2025.
By Exponent, Inc. · Via GlobeNewswire · July 31, 2025
Cemtrex Acquires $1 Million in Solana, Citing Structural Mispricing; Targets $10 Million Crypto Treasury Reserve
Hauppauge, NY, July 31, 2025 (GLOBE NEWSWIRE) --  Cemtrex Inc. (Nasdaq: CETX), a technology company focused on intelligent security systems and industrial services, today announced it has acquired approximately $1 million worth of Solana (SOL) as part of a new digital asset treasury strategy, with the goal of expanding its crypto reserves to $10 million over time.
By Cemtrex Inc. · Via GlobeNewswire · July 31, 2025
Avista Makes Annual Price Adjustment Filings in Idaho
Requests would result in higher electric prices effective Oct. 1, 2025 and lower natural gas prices effective Nov. 1, 2025.
By Avista Corporation · Via GlobeNewswire · July 31, 2025
Fidus Investment Corporation Schedules Second Quarter 2025 Earnings Release and Conference Call
EVANSTON, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ: FDUS) (“Fidus” or the “Company”) today announced that it will report its second quarter 2025 financial results on Thursday, August 7, 2025 after the close of the financial markets.
By Fidus Investment Corporation · Via GlobeNewswire · July 31, 2025
Navitas Powers Xiaomi’s Next Generation GaN Charger
GaNSense™ Control ICs drive Xiaomi’s 90W next-gen GaN charger, setting new standards for performance, size, and weight in ultra-portable fast charging.
NCS Multistage to Acquire ResMetrics, Further Expanding Tracer Diagnostics Offering
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (NASDAQ:NCSM) (“NCS” or the “Company”) today announced that it has acquired ResMetrics LLC (“ResMetrics”), a leading provider of chemical tracer diagnostics services used by oil and gas operators to validate reservoir development strategies, improve hydraulic fracture stimulation designs, evaluate inter-well connectivity, and optimize enhanced oil recovery injection programs, complementing and further strengthening NCS’s tracer diagnostics capabilities.
By NCS Multistage Holdings, Inc. · Via GlobeNewswire · July 31, 2025
EPE Vape Trinity 45000 Puffs Just Hacked Festival Season – Meet the Ultimate Party Sidekick!
Contact Info: Name: EPE Vape Team Email: Send Email Organization: EPE Vape Website: http://www.epevape.com
Weave Announces Second Quarter 2025 Financial Results
Weave Communications, Inc. (“Weave”) (NYSE: WEAV), a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses, today announced its financial results for the second quarter June 30, 2025.
By Weave Communications, Inc. · Via Business Wire · July 31, 2025
Huron Acquires Global Financial Services Consulting Firm Treliant
Global professional services firm Huron (NASDAQ: HURN) today announced it has acquired Treliant, LLC, a leading advisory and managed services partner to the financial services industry. This acquisition expands Huron’s Commercial segment offerings and enhances the firm’s ability to help financial institutions navigate today’s increasingly complex macroeconomic and regulatory environment.
By Huron · Via Business Wire · July 31, 2025
Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock (the “Offering”). All of the securities are being offered by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock and pre-funded warrants sold in the Offering at the public offering price per share, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
First Solar, Inc. Announces Second Quarter 2025 Financial Results and Updates Guidance
First Solar, Inc. (Nasdaq: FSLR) (the “Company”) today announced financial results for the second quarter ended June 30, 2025, and updated its 2025 guidance.
By First Solar, Inc. · Via Business Wire · July 31, 2025
Backblaze to Sponsor Ai4 2025 Conference Showcasing New B2 Overdrive Storage for AI and HPC Workflows
Backblaze, Inc. (Nasdaq: BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, continues their push to provide enterprises with better cloud storage infrastructure options for AI workflows by being a Gold-level sponsor at Ai4 2025 in Las Vegas August 11–13.
By Backblaze, Inc. · Via Business Wire · July 31, 2025
Huron Amends and Extends Senior Secured Credit Facility
Global professional services firm Huron (NASDAQ: HURN) today announced the successful refinancing and expansion of its senior secured credit facility.
By Huron · Via Business Wire · July 31, 2025
WillScot Reports Second Quarter 2025 Results and Updates 2025 Full Year Outlook
PHOENIX, July 31, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced second quarter 2025 results, including key performance highlights, market updates, and narrowed its original 2025 full year outlook.
By WillScot · Via GlobeNewswire · July 31, 2025
StoneX Completes Acquisition of R.J. O’Brien, Becoming the Largest Non-Bank FCM in the United States and Enhancing Global Multi-Asset Capabilities
The most significant acquisition in StoneX history unites two of the most well-respected names in the futures industry, combining 200+ years of derivatives expertise
By StoneX Group Inc. · Via GlobeNewswire · July 31, 2025
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share • Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers
Strategy Announces Second Quarter 2025 Financial Results; Record Net Income of $10.0 Billion and EPS of $32.60
MicroStrategy® Incorporated d/b/a Strategy™ (Nasdaq: MSTR/STRK/STRF/STRD/STRC) (“Strategy” or the “Company”), the largest corporate holder of bitcoin and the world’s first Bitcoin Treasury Company, today announces financial results for the three-month period ended June 30, 2025 (the second quarter of its 2025 fiscal year).
By Strategy · Via Business Wire · July 31, 2025
Amazon.com Announces Second Quarter Results
Amazon.com, Inc. (NASDAQ: AMZN) today announced financial results for its second quarter ended June 30, 2025.
By Amazon.com, Inc. · Via Business Wire · July 31, 2025
CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the presentation of several high-impact studies and digital health innovations by independent research teams at the 2025 World Transplant Congress (WTC), demonstrating advances in artificial intelligence, predictive diagnostics, transplant access, and organ-specific innovation.
By CareDx, Inc. · Via Business Wire · July 31, 2025
Aeva Unveils Vision for the Future of Sensing and Perception and Reports Second Quarter 2025 Results at Aeva Day
Aeva® (NASDAQ: AEVA), a leader in next-generation sensing and perception systems, today hosted Aeva Day: Beyond the Beam in New York City, where the company showcased how its unique perception platform can enable the future of sensing and perception across multiple applications and industries at mass scale. At the event, key customers, partners and industry leaders shared their insights on Aeva’s differentiated performance and the growing trend towards FMCW technology.
By Aeva Technologies, Inc. · Via Business Wire · July 31, 2025
Perdoceo Education Corporation Reports Second Quarter and Year to Date 2025 Results
Perdoceo Education Corporation (NASDAQ: PRDO), a provider of postsecondary education programs, today reported operating and financial results for the quarter and year to date ended June 30, 2025.
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen’s capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein design to biologics discovery. Dr. Deshaies completed his tenure at Amgen as a distinguished fellow.
By Xencor, Inc. · Via Business Wire · July 31, 2025
NetApp Hosts First Quarter of Fiscal Year 2026 Financial Results Webcast
After market close on August 27, 2025, NetApp (NASDAQ: NTAP) will announce financial results for the first quarter of fiscal year 2026, which ended July 25, 2025.
By NetApp · Via Business Wire · July 31, 2025
Rimini Street Announces Fiscal Second Quarter 2025 Financial and Operating Results
Rimini Street, Inc., (the “Company”) (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2025.
By Rimini Street, Inc. · Via Business Wire · July 31, 2025
MindMed Reports Q2 2025 Financial Results and Business Updates
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights.
By Mind Medicine Inc. · Via Business Wire · July 31, 2025
Credit Acceptance Announces Second Quarter 2025 Results
Southfield, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) today announced consolidated net income of $87.4 million, or $7.42 per diluted share, for the three months ended June 30, 2025. Adjusted net income, a non-GAAP financial measure, for the three months ended June 30, 2025 was $100.8 million, or $8.56 per diluted share. The following table summarizes our financial results:
By Credit Acceptance Corporation · Via GlobeNewswire · July 31, 2025
WillScot Declares Quarterly Cash Dividend
PHOENIX, July 31, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that its Board of Directors has declared a quarterly dividend of $0.07 per common share. The cash dividend will be paid on September 17, 2025, to shareholders of record as of the close of business on September 3, 2025.
By WillScot · Via GlobeNewswire · July 31, 2025
Macerich Declares the Quarterly Dividend on Its Common Shares
SANTA MONICA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of the Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on September 23, 2025, to stockholders of record at the close of business on September 9, 2025.
By Macerich Company · Via GlobeNewswire · July 31, 2025
National Healthcare Properties Announces Release Date for Second Quarter 2025 Results
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (“NHP”) announced today that it will release its financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after market close.
Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
BOSTON, MA / ACCESS Newswire / July 31, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today that the U.S. District Court for the District of Massachusetts has ruled in favor of Radius and co-plaintiff Ipsen Pharma S.A.S. ("Ipsen") in a patent infringement suit against Orbicular Pharmaceutical Technologies Private Ltd. ("Orbicular") for their proposed generic for TYMLOS® (abaloparatide) for osteoporosis. Radius and Ipsen prevailed, and the court upheld the validity of all five TYMLOS® patents asserted, in which the latest to expire will remain in effect through April 30, 2038.
Via ACCESS Newswire · July 31, 2025
Altigen Technologies Reports Third Quarter Results for Fiscal Year 2025
NEWARK, CALIFORNIA / ACCESS Newswire / July 31, 2025 / Altigen Technologies (OTCQB:ATGN), a leading Silicon Valley-based Microsoft Cloud Communications Solutions provider, announced today its financial results for the third quarter ended June 30, 2025.
Via ACCESS Newswire · July 31, 2025
Pacer ETFs Announces Fee Reduction on Four Funds
Pacer ETFs (“Pacer”), the leading U.S. issuer in free cash flow ETFs*, announces the reduction of fees across four of its ETFs effective as of August 1, 2025. The following funds have had their management fees reduced from 0.60% to 0.49%:
By Pacer ETFs · Via Business Wire · July 31, 2025
Cohu Reports Second Quarter 2025 Results
Cohu, Inc. (NASDAQ: COHU), a global supplier of equipment and services optimizing semiconductor manufacturing yield and productivity, today reported fiscal 2025 second quarter net sales of $107.7 million and GAAP loss of $16.9 million or $0.36 per share. Net sales for the first six months of 2025 were $204.5 million and GAAP loss was $47.7 million or $1.02 per share.
By Cohu, Inc. · Via Business Wire · July 31, 2025
Lattice Wins Most Innovative Hardware Company of the Year at 2025 Globee® Awards for Technology
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced it was named ‘Most Innovative Company of the Year’ in the Hardware category at the 20th Annual 2025 Globee Awards for Technology. The award recognizes Lattice’s continued leadership in delivering flexible FPGA solutions that set new standards for power efficiency, performance, and impact across global markets.
By Lattice Semiconductor · Via Business Wire · July 31, 2025
Intuit to Announce Fourth-Quarter and Full-Year Fiscal 2025 Results on Aug. 21; Investor Day Set for Sep. 18
Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes Intuit TurboTax, Credit Karma, QuickBooks, and Mailchimp, will announce its fourth-quarter and full-year financial results for fiscal year 2025 on August 21, following the close of market. The company’s fourth quarter ends on July 31.
By Intuit Inc. · Via Business Wire · July 31, 2025
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
By INVENTIVA · Via GlobeNewswire · July 31, 2025
RCKT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · July 31, 2025